$EQ

Zedelmayer Christine sold $150K of EQ

Zedelmayer Christine (Sr. Vice President and COO) sold 55,604 shares of Equillium, Inc. (EQ) at $2.70 ($0.15M total) on 2026-05-28 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Zedelmayer Christine
Published May 29, 2026, 10:19 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 29, 2026, 10:20 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$EQ
Neutral
medium confidence
Mentioned
$EQ
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EQNeutralLow
01

Why it matters

The disclosure updates the record of insider activity (COO selling) but does not provide new company fundamentals; the 10b5-1 plan suggests the trades were scheduled in advance.

02

Market read

Traders may monitor EQ for any follow-on insider activity, but this specific filing is unlikely to drive a durable repricing by itself.

03

What to watch

Check whether there are multiple insider transactions around the same period or any concurrent changes in trading plans; one Form 4 alone is usually not decisive.

Relevance 6/10Novelty 3/10Timing: Filed 2026-05-29; reflects sale executed 2026-05-28.

Background

This is an SEC Form 4 insider transaction disclosure for Equillium, Inc. (EQ).

Company-level read

Ticker impact

$EQNeutralMedium confidence
Context

Equillium COO Christine Zedelmayer sold 55,604 shares ($150,130.80) via an open-market transaction under a 10b5-1 plan.

Expected impact

Limited, mostly sentiment/positioning impact; no clear directional catalyst implied by the filing alone.

Evidence & confidence

The filing is a routine insider transaction with explicit 10b5-1 pre-arrangement, which typically reduces interpretability as a new negative information signal.

Market effects

Minimal—single-company insider transaction without accompanying operational/regulatory/drug-trial news.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, the market may overreact; price impact could fade quickly if no other catalysts exist.

Key entities

  • Equillium, Inc.

    Subject of the insider transaction disclosure (COO sale under a 10b5-1 plan).

  • Christine Zedelmayer

    COO who sold 55,604 shares on 2026-05-28.

Related articles

$EQMedAI 8/10

Equillium Links AhR Activation to miR-124 as EQ504 Heads Toward Phase 1

Equillium (NASDAQ:EQ) presented preclinical data linking aryl hydrocarbon receptor (AhR) activation to miR-124 induction, led by CSO Stephen Connelly. Using its AhR modulator EQ504 and Abivax’s obefazimod (ABX464), the company reported miR-124 induction in immune cells with AhR antagonism reducing it, alongside decreases in pro-inflammatory cytokines. ABX464 showed an AhR EC50 ~400 nM in reporter assays. Equillium said Phase 1 readouts will focus on colon tissue drug exposure (EC50–EC90) and CYP